GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Krystal Biotech Inc (NAS:KRYS) » Definitions » Degree of Operating Leverage

KRYS (Krystal Biotech) Degree of Operating Leverage : -1.38 (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Krystal Biotech Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Krystal Biotech's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was -1.38. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for Krystal Biotech's Degree of Operating Leverage or its related term are showing as below:

KRYS's Degree of Operating Leverage is ranked better than
75.63% of 878 companies
in the Biotechnology industry
Industry Median: -0.025 vs KRYS: -1.38

Krystal Biotech Degree of Operating Leverage Historical Data

The historical data trend for Krystal Biotech's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Krystal Biotech Degree of Operating Leverage Chart

Krystal Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only - - - - -0.44

Krystal Biotech Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -0.05 -0.44 -1.38

Competitive Comparison of Krystal Biotech's Degree of Operating Leverage

For the Biotechnology subindustry, Krystal Biotech's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Krystal Biotech's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Krystal Biotech's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Krystal Biotech's Degree of Operating Leverage falls into.


;
;

Krystal Biotech Degree of Operating Leverage Calculation

Krystal Biotech's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( 133.555 (Mar. 2025) / -55.087 (Mar. 2024) - 1 )/( 333.447 (Mar. 2025) / 95.949 (Mar. 2024) - 1 )
=-3.4244/2.4753
=-1.38***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Krystal Biotech  (NAS:KRYS) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Krystal Biotech Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Krystal Biotech's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Krystal Biotech Business Description

Traded in Other Exchanges
Address
2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Executives
Krish S Krishnan director, 10 percent owner, officer: President and CEO 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Suma Krishnan director, 10 percent owner, officer: Chief Operating Officer 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Kathryn Romano officer: Chief Accounting Officer C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Julian S Gangolli director 4955 BASELINE AVENUE, SANTA YNEZ CA 93460
Catherine Mazzacco director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Daniel Janney director PO BOX 7414, JACKSON WY 83002
Andrew C. Orth officer: Chief Commercial Officer 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Dino A Rossi director 61 WATROO POINT, DANIEL ISLAND SC 29492
Everett Rand Sutherland director 29 HARTWELL AVENUE, LEXINGTON MA 02421
Christopher Mason director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Jing L. Marantz director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Jennifer Chien officer: Chief Commercial Officer C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Antony A Riley officer: Chief Financial Officer C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 94538
R Douglas Norby director C/O MAGNACHIP SEMICONDUCTOR, INC., 20400 STEVENS CREEK BOULEVARD, SUITE 370, CUPERTINO CA 95014
Sun Pharma (netherlands) B.v. 10 percent owner POLARISAVENUE 87, 2132 JH HOOFDDORP P7 00000